Alphabet’s Calico Life Sciences has inked a licensing deal worth up to $571 million with China-based Mabwell Bioscience to acquire exclusive global rights (excluding greater China) to 9MW3811, a clinical-stage monoclonal antibody targeting IL-11, implicated in age-related diseases and idiopathic pulmonary fibrosis. Mabwell has conducted phase 1 trials in China and Australia and holds an active FDA investigational new drug application for the asset. This partnership aligns with Calico’s mission to develop interventions in the biology of aging, complementing existing collaborations with AbbVie and the Broad Institute.